A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Inclusion Criteria: * • Patients must have one of the following histologies with molecularly-confirmed diagnosis that is recurrent or progressive. Patients enrolled will be stratified as follows: * Phase I: * Stratum 1 LGG or HGG with BRAF V600E/D/K mutation * Stratum 2 LGG with BRAF duplication or fusion with any partner or LGG with neurofibromatosis type 1 * Phase II: * Stratum 3 LGG with BRAF V600E/D/K mutation * Stratum 4 HGG with BRAF V600E/D/K mutation * Stratum 5 LGG with BRAF duplication or fusion with any partner * Stratum 6 LGG with neurofibromatosis type 1 * BRAF alterations will be locally determined using molecular methods in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory. Immunohistochemistry for BRAF V600E alone is not adequate and must be confirmed molecularly * Phase II patients must have bi-dimensionally measurable disease defined as at least one lesion that can be accurately measured in at least two planes. A target lesion should be chosen * Patients are required to have weight \>= 9 kg to enroll on any stratum in the Phase I or Phase II * Phase I only * Patients enrolled on the 8 mg/kg/day (dose level 1) must have a weight \< 90 kg * Patients enrolled on the 15 mg/kg/day (dose level 2) must have a weight \< 80 kg * Patients enrolled on the 20 mg/kg/day (dose level 3) must have a weight \< 68 kg * Patients must have received prior therapy other than surgery and must have ful…